RSI Overbought Stocks
DAWN is RSI overbought, meaning strong buying pressure may lead to a short-term consolidation or pullback.
DAY ONE BIOPHARMACEUTICALS I (DAWN) Stock Price & Overview
NASDAQ:DAWN • US23954D1090
Current stock price
21.44 USD
0 (0%)
Last:
The current stock price of DAWN is 21.44 USD. Today DAWN is down by 0%. In the past month the price increased by 113.76%. In the past year, price increased by 196.95%.
DAWN Key Statistics
52-Week Range5.635 - 21.46
Current DAWN stock price positioned within its 52-week range.
1-Month Range10.02 - 21.46
Current DAWN stock price positioned within its 1-month range.
- Market Cap
- 2.215B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.04
- Dividend Yield
- N/A
DAWN Stock Performance
Today
0%
1 Week
+0.28%
1 Month
+113.76%
3 Months
+142.26%
Longer-term
6 Months +169.69%
1 Year +196.95%
2 Years +29.78%
3 Years +60.36%
5 Years N/A
10 Years N/A
DAWN Stock Chart
DAWN Stock Screens
DAWN currently appears in the following ChartMill screener lists.
Bull Flag Stocks
DAWN is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
DAWN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DAWN. When comparing the yearly performance of all stocks, DAWN is one of the better performing stocks in the market, outperforming 98.2% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DAWN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to DAWN. While DAWN has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DAWN Earnings
On February 24, 2026 DAWN reported an EPS of -0.21 and a revenue of 53.72M. The company missed EPS expectations (-35.56% surprise) and beat revenue expectations (8.44% surprise).
Next Earnings DateMay 1, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.21
Revenue Reported53.718M
EPS Surprise -35.56%
Revenue Surprise 8.44%
DAWN Forecast & Estimates
15 analysts have analysed DAWN and the average price target is 21.17 USD. This implies a price decrease of -1.28% is expected in the next year compared to the current price of 21.44.
For the next year, analysts expect an EPS growth of 23.71% and a revenue growth 56.78% for DAWN
Analysts
Analysts82.67
Price Target21.17 (-1.26%)
EPS Next Y23.71%
Revenue Next Year56.78%
DAWN Groups
Sector & Classification
DAWN Financial Highlights
Over the last trailing twelve months DAWN reported a non-GAAP Earnings per Share(EPS) of -1.04. The EPS increased by 41.57% compared to the year before.
Income Statements
Revenue(TTM)158.18M
Net Income(TTM)-107.32M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.13% | ||
| ROE | -24.33% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%67.19%
Sales Q2Q%83.97%
EPS 1Y (TTM)41.57%
Revenue 1Y (TTM)20.6%
DAWN Ownership
Ownership
Inst Owners77.97%
Shares103.30M
Float83.84M
Ins Owners2.41%
Short Float %9.65%
Short Ratio1.67
DAWN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.47 | 384.559B | ||
| AMGN | AMGEN INC | 15.5 | 189.672B | ||
| GILD | GILEAD SCIENCES INC | 15.82 | 173.017B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.17 | 113.435B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.61 | 81.684B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 43.88B | ||
| INSM | INSMED INC | N/A | 35.247B | ||
| NTRA | NATERA INC | N/A | 28.345B | ||
| BIIB | BIOGEN INC | 11.42 | 26.906B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.33 | 25.99B | ||
| MRNA | MODERNA INC | N/A | 20.063B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.272B | ||
| INCY | INCYTE CORP | 12.35 | 18.731B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DAWN
Company Profile
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 178 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
Company Info
IPO: 2021-05-27
DAY ONE BIOPHARMACEUTICALS I
1800 Sierra Point Parkway, Suite 200
Brisbane California CALIFORNIA US
CEO: Jeremy Bender
Employees: 182
Phone: 16504840899
DAY ONE BIOPHARMACEUTICALS I / DAWN FAQ
Can you describe the business of DAY ONE BIOPHARMACEUTICALS I?
Day One Biopharmaceuticals, Inc. operates as a holding company. The company is headquartered in Brisbane California, California and currently employs 178 full-time employees. The company went IPO on 2021-05-27. The company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
What is the current price of DAWN stock?
The current stock price of DAWN is 21.44 USD.
Does DAY ONE BIOPHARMACEUTICALS I pay dividends?
DAWN does not pay a dividend.
How is the ChartMill rating for DAY ONE BIOPHARMACEUTICALS I?
DAWN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy DAWN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DAWN.
What is the market capitalization of DAWN stock?
DAY ONE BIOPHARMACEUTICALS I (DAWN) has a market capitalization of 2.21B USD. This makes DAWN a Mid Cap stock.